Thursday 30 October, Riyadh – CSL Seqirus and Vaccine Industrial Company, have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology...

INTENDED FOR MEDIA AND BUSINESS INVESTORS ONLY Summit, New Jersey, USA | 21 October, 2025 – CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable...

Summit, New Jersey, USA | 17 October 2025 – CSL Seqirus, a business of CSL (ASX:CSL) today announced that it will be presenting 14 abstracts at the European Scientific Working group on Influenza...

CSL Seqirus to provide pandemic influenza vaccine to support 17 EU and EEA countries and the EU Commission in the event of a pandemic declaration. The decision by the Health Emergency Preparedness...

To date, there have been over 46,300 lab-confirmed influenza cases in Australia, more than 50% higher than the previous record of flu cases in Australia during the first quarter (January – March...

Melbourne, 4 March 2025 – CSL Seqirus and Esperion Therapeutics have today announced the signing of an exclusive license and distribution agreement to commercialize Nexletol® (bempedoic acid)...

As we approach the OPTIONS XII for the Control of Influenza, a global scientific meeting that focuses on influenza, there is an enormous sense of pride among all of us at CSL Seqirus. For the...

CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and poultry have...

Throughout 2023 and 2024, outbreaks of highly pathogenic avian influenza (HPAI) viruses among birds have been reported in several regions including Africa, Asia, Europe, and North America...

Under the licensing and distribution agreement, CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialisation of neffyTM (adrenaline nasal spray) ARS...

March 7, 2024 During the latter part of 2023 and following notification by the World Health Organization that B/Yamagata lineage viruses have not been confirmed as detected in circulation since...

CSL Seqirus will provide its registered pandemic influenza vaccine to the UK if an influenza pandemic occurs during the next four years. This new agreement to CSL Seqirus follows more than ten...

CSL Seqirus presents new data at the 9th ESWI meeting on the impact of effective vaccination campaigns to protect healthcare systems across the world.1,2 The French data highlights how vaccines...

SUMMIT, N.J., September 15, 2023 -- CSL Seqirus, a business of CSL (ASX:CSL), today announced new data that will be presented at the European Scientific Working Group on Influenza (ESWI)...

CSL Seqirus is the only influenza vaccine manufacturer that offers differentiated vaccine options for individuals six months of age and older. Since the COVID-19 pandemic, there has been a...

Melbourne, Monday 22 May CSL Seqirus has today announced that construction of its new state-of-the-art manufacturing facility in Australia has reached its highest point, known as ‘topping...

Melbourne, 1 March 2023 CSL Seqirus (Seqirus Pty Ltd) and Amarin Corporation plc (NASDAQ:AMRN) have today announced the signing of an exclusive license and distribution agreement to commercialise...

CSL to access late-stage next-generation mRNA platform technology, enabling development of vaccines for COVID-19, influenza, multi-pathogen pandemic preparedness and other respiratory pathogens...

Data published in Molecular Therapy – Methods and Clinical Development confirm the potential preclinical benefit of the sa-mRNA technology platform, the next generation of mRNA vaccine technology

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data highlighting the significant burden influenza places on hospitals and healthcare resource use, as well as on more...

CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studies showing the impact that cell-based and adjuvanted influenza vaccines can have in reducing...

CSL Seqirus, a part of CSL Limited (ASX:CSL), today announced new data will be presented at the Options for the Control of Influenza (OPTIONS XI) conference taking place September 26-29, 2022 in...

Seqirus – a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), – has entered into a multi-year influenza research partnership with the University of Liverpool Pandemic Institute. Under the partnership, Seqirus will participate in research projects and knowledge generation around both the threat of seasonal influenza and the development of innovative approaches to pandemic preparedness and response.

Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced the completion of an expansion to the company’s manufacturing facility in Holly Springs, N.C., supporting the formulation and fill-finish of its cell-based influenza vaccines in pre-filled syringes for global communities.

• Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA) to strengthen preparedness and rapid response...